ArticleACG case reports journal2019
Nivolumab-Induced Concomitant Severe Upper and Lower Gastrointestinal Immune-Related Adverse Effects.
Article in ACG case reports journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 22 citations in OpenAlex.
- Rare occurrence of immunotherapy-related gastritis and duodenitis in a single tertiary medical center: a diagnostic challenge.The oncologist · 2025Article
- Endoscopic insights into digestive-related adverse effects of immune checkpoint inhibitors: A narrative review.World journal of gastrointestinal endoscopy · 2025Review
- Immune checkpoint inhibitor-associated gastritis: Patterns and management.World journal of gastroenterology · 2024Article
- Nivolumab-induced tumour-like gastritis: A case report.World journal of clinical cases · 2023Article
- Article
- Severe immune checkpoint inhibitor-associated gastritis: A case series and literature review.Endoscopy international open · 2022Article
- Temporal observation of endoscopic and histological findings of gastritis after administration of an immune checkpoint inhibitor: a case report.Clinical journal of gastroenterology · 2022Article
- Timeline of Adverse Events during Immune Checkpoint Inhibitors for Advanced Melanoma and Their Impacts on Survival.Cancers · 2022Article
- Gastrointestinal adverse events of immunotherapy.BJR open · 2021Review
- Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management.Frontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunotherapy agents such as cytotoxic T-lymphocyte antigen-4 and programed cell death protein-1 inhibitors show efficacy in cancer therapy but are associated with immune-related adverse events. It commonly presents as diarrhea but can cause colitis, mimicking inflammatory bowel disease. Our patient is a 78-year-old man on nivolumab therapy for metastatic lung cancer who developed new onset nausea and diarrhea. Endoscopy revealed inflammation of the upper and lower gastrointestinal tract, and histology revealed transmural colon and gastric inflammation. We present a fascinating case of severe concomitant aphthous ulcers, esophagitis, gastritis, and enterocolitis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.